StockIceMan's Weekly Stock Pick
Week of
May 2, 2005
| Stock: |
Elan Corporation Plc.
|
|
|
| Ticker Symbol: |
ELN - NYSE - Pharmaceuticals |
|
|
| Buy: |
5.00 to 5.40 |
|
|
| Sell: |
7.00 |
|
|
|
Info: |
Elan Corporation, plc is a
neuroscience-based biotechnology company that
focuses on discovering, developing,
manufacturing and marketing advanced therapies
in neurology, autoimmune diseases and severe
pain. Elan markets two products in the United
States: AZACTAM (aztreonam for injection, USP)
and MAXIPIME (cefepime hydrochloride) for
Injection. AZACTAM is a monobactam indicated for
the treatment of the infections caused by
susceptible gram-negative microorganisms and is
principally used by surgeons, infectious disease
specialists and internal medicine physicians to
treat pneumonia, post-surgical infections and
septicemia. MAXIPIME for Injection is a
semi-synthetic, broad-spectrum, cephalosporin
antibiotic used by pulmonologists, infectious
disease specialists, internal medicine
physicians, hematologists and oncologists to
treat patients with serious and/or potentially
life-threatening infections. |
|
|
| Financial Info: |
For the fiscal year ended
12/31/04, revenues fell 30% to $481.7 million.
Net loss from continuing operations fell 13% to
$413.7 million |
|
|
| Key Ratios: |
Current
Ratio: 3.92, Total Debt/Equity:11.22, Trailing
P/E: N/A, Forward P/E: N/A, Price/Book:
9.04, Price/Sales: N/A |
|
|
| Share Info: |
There are 395.10
million shares outstanding with 387.20
million shares in the trading
float. Institutions own
approximately 53.73% of the shares outstanding.
There have been no reported insider purchases
or sales in the last six months.
Real-Time SEC
Filings
As of 3/8/2005, there were 29.38 million shares short.
Net Institutional Buying: : 3.347 million
shares prior to latest
quarter. |
|
|
| Articles: |
Elan shares leap as
investors take bet on MS drug |
|
